Little Darren J, Ballo Matthew T, Zagars Gunar K, Pisters Peter W T, Patel Shreyaskumar R, El-Naggar Adel K, Garden Adam S, Benjamin Robert S
Department of Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2002 Jul 15;95(2):377-88. doi: 10.1002/cncr.10669.
Childhood rhabdomyosarcoma (RMS) has a relatively good prognosis. Outcome for adults with this disease is poorly documented due to its rarity.
The clinicopathologic features, treatment methods, and disease outcome were reviewed retrospectively for 82 adults with locoregional RMS treated between 1960 and 1998. Patients with distant metastasis at diagnosis were excluded. Actuarial univariate and multivariate statistical methods were used to evaluate outcome.
Patient ages ranged from 17 to 84 years (median, 27 years). Histologic subtypes were embryonal (34%), pleomorphic (43%), and alveolar (23%). Anatomic sites of origin were head and neck (52%), trunk (26%), and extremity (7%). Tumor size was 5 cm or smaller in 51% of patients. Regional lymph node metastasis was present in 33% of patients at presentation. Treatment consisted of radiation alone in 11%, radiation and surgery in 18%, radiation and chemotherapy in 34%, and all three modalities in 37%. With a median follow-up of 10.5 years, the 10-year actuarial disease-free and overall survival rates were 41% and 40%, respectively. The 10-year actuarial local, lymph node, and metastatic control rates were 75%, 82%, and 53%, respectively. The major determinant of metastatic control and survival was primary tumor size (< or = 5 vs. > 5 cm). Local control was satisfactory (10-year rate of 87%) for sites other than parameningeal (50% at 10 years). Patients whose disease responded to chemotherapy had a significantly better metastasis free period (72% at 10 years) than those whose disease failed to respond (19% at 10 years).
Adult RMS is a highly malignant tumor with a significant incidence of metastatic recurrence. Continuing investigation of new and potentially more effective chemotherapy is crucial. Local control is satisfactory for sites other than parameningeal where new radiation technologies such as intensity-modulated therapy may be necessary to safely deliver adequate doses.
儿童横纹肌肉瘤(RMS)预后相对较好。由于成人患此病较为罕见,关于成人患者的疾病转归记录较少。
回顾性分析1960年至1998年间接受治疗的82例局限性RMS成年患者的临床病理特征、治疗方法及疾病转归。排除诊断时已有远处转移的患者。采用精算单因素和多因素统计方法评估转归。
患者年龄为17至84岁(中位年龄27岁)。组织学亚型包括胚胎型(34%)、多形型(43%)和肺泡型(23%)。原发部位为头颈部(52%)、躯干(26%)和四肢(7%)。51%的患者肿瘤大小为5 cm或更小。33%的患者初诊时存在区域淋巴结转移。治疗方式包括单纯放疗(11%)、放疗加手术(18%)、放疗加化疗(34%)以及三种方式联合(37%)。中位随访10.5年,10年精算无病生存率和总生存率分别为41%和40%。10年精算局部、淋巴结和远处转移控制率分别为75%、82%和53%。远处转移控制和生存的主要决定因素是原发肿瘤大小(≤5 cm与>5 cm)。除脑膜旁部位外,其他部位的局部控制效果良好(10年局部控制率为87%,脑膜旁部位10年局部控制率为50%)。疾病对化疗有反应的患者无转移生存期明显长于无反应者(10年时分别为72%和19%)。
成人RMS是一种高度恶性肿瘤,远处转移复发率较高。持续研究新的、可能更有效的化疗方法至关重要。除脑膜旁部位外,其他部位的局部控制效果良好,在脑膜旁部位可能需要采用如调强放疗等新的放疗技术以安全给予足够剂量。